While small observational studies showed that MRAs can be efficacious for blood pressure control and cardiovascular protection even in low doses (14–16), large retrospective cohort studies of patients with PA and essential hypertension suggest that the cardio-renal benefits of MRA therapy in PA patients are maximized when renin is no longer suppressed (4, 17, 18). Here, REN is linked to essential hypertension.